Search the GHTC website

Global health R&D delivers for New York

US government investment in global health R&D has delivered

Amount
$916.0 million
to New York research institutions
Jobs
9,600+ new jobs
for New York
Global health R&D at work in New York

The International AIDS Vaccine Initiative (IAVI) is working to develop HIV vaccines and other prevention tools. Research by IAVI and partners has yielded insights into how the immune system attempts to control the virus, how HIV evades immune defenses, how disease progression varies by virus strain, and how some people living with HIV naturally produce antibodies against a broad array of HIV types. IAVI is supporting development and testing of 11 vaccine candidates.

Footnotes
  • Methodology
  • USG global health R&D investment to state research institutions/Top USG-funded global health R&D institutions: Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007–2015 and for Ebola and select viral hemorrhagic fevers from 2014–2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See methodology for additional details.
  • Jobs created: Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See methodology for additional details.
  • Case study photo: International AIDS Vaccine Initiative